272 related articles for article (PubMed ID: 20689641)
1. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA; Field SK
Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
[TBL] [Abstract][Full Text] [Related]
2. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
3. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Roflumilast in Korean Patients with COPD.
Lee JS; Hong YK; Park TS; Lee SW; Oh YM; Lee SD
Yonsei Med J; 2016 Jul; 57(4):928-35. PubMed ID: 27189287
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of roflumilast in moderate to severe COPD.
Yu T; Fain K; Boyd CM; Singh S; Weiss CO; Li T; Varadhan R; Puhan MA
Thorax; 2014 Jul; 69(7):616-22. PubMed ID: 24347460
[TBL] [Abstract][Full Text] [Related]
6. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.
Kardos P; Mokros I; Sauer R; Vogelmeier CF
Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213
[TBL] [Abstract][Full Text] [Related]
7. Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast.
Barnes NC; Saetta M; Rabe KF
BMC Pulm Med; 2014 Jan; 14():9. PubMed ID: 24484726
[TBL] [Abstract][Full Text] [Related]
8. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Grootendorst DC; Gauw SA; Verhoosel RM; Sterk PJ; Hospers JJ; Bredenbröker D; Bethke TD; Hiemstra PS; Rabe KF
Thorax; 2007 Dec; 62(12):1081-7. PubMed ID: 17573446
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A
J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099
[TBL] [Abstract][Full Text] [Related]
10. Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease.
Fu AZ; Sun SX; Huang X; Amin AN
Int J Chron Obstruct Pulmon Dis; 2015; 10():909-15. PubMed ID: 25999706
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
12. Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
S SLJ; V R
Pulm Pharmacol Ther; 2021 Feb; 66():101978. PubMed ID: 33259924
[TBL] [Abstract][Full Text] [Related]
13. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
Boswell-Smith V; Spina D
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):121-9. PubMed ID: 18044684
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast.
Fabbri LM; Beghé B; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 Oct; 9(10):761-2. PubMed ID: 20885403
[No Abstract] [Full Text] [Related]
15. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
16. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
de Mey C; Nassr N; Lahu G
BMC Clin Pharmacol; 2011 Jun; 11():7. PubMed ID: 21631929
[TBL] [Abstract][Full Text] [Related]
17. Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation.
Zheng XF; Chen DD; Zhu XL; Le Grange JM; Zhou LQ; Zhang JN
Pharmacol Res Perspect; 2021 Aug; 9(4):e00840. PubMed ID: 34327862
[TBL] [Abstract][Full Text] [Related]
18. Topical and Oral Roflumilast in Dermatology: A Narrative Review.
Mansilla-Polo M; Gimeno E; Morgado-Carrasco D
Actas Dermosifiliogr; 2024 Mar; 115(3):265-279. PubMed ID: 37709133
[TBL] [Abstract][Full Text] [Related]
19. The Dosing Strategy to Improve Adherence to Roflumilast in Treatment for Chronic Obstructive Lung Disease: A Systemic Review and Meta-Analysis.
Lee J; Song JU
Int J Chron Obstruct Pulmon Dis; 2024; 19():655-663. PubMed ID: 38476122
[TBL] [Abstract][Full Text] [Related]
20. Vulnerable COPD patients with comorbidities: the role of roflumilast.
Lipari M; Kale-Pradhan PB
Ther Clin Risk Manag; 2014; 10():969-76. PubMed ID: 25429225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
